Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

References

• KondoSアルベカシンの開発とメチシリン耐性黄色ブドウ球菌による酵素的修飾をうけない新規誘導体の合成. [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus]Jpn J Antibiot1994476561574 Japanese8072163
   PubMedGoogle Scholar
• TanakaNMatsunagaKHirataAMatsuhisaYNishimuraTMechanism of action of Habekacin, a novel amino acid containing aminoglycoside antibioticAntimicrob Agents Chemother19832457978026362557
   PubMed Web of Science ®Google Scholar
• WatanabeAYanagiharaKMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother201218560962022766652
   PubMed Web of Science ®Google Scholar
• YamaguchiKIshiiYIwataMMeropenem を含む各種注射用抗菌薬に対する2006年臨床分離株の感受性サーベイランス. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006]Jpn J Antibiot2007606344377 Japanese18447206
   PubMedGoogle Scholar
• NishinoTSakuraiMIn vitro activity of everninomicin (SCH 27899)Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and ChemotherapyOctober 17–20, 1993Louisiana, New Orleans Abstract No 462
   Google Scholar
• OkamotoRIyobeSMitsuhashiSHBKの細菌学的検討 [Antibacterial activity of HBK]Chemother198634110 Japanese
   Google Scholar
• KazunoYTsunetaSTamraABactriological evaluation of a new aminoglycoside antibiotic, HBKChemother1986346171
   Google Scholar
• MatsuhashiYYamamotoHメチシリン・セフェム耐性黄色ブドウ球菌の産生するアミノ配糖体系抗生物質不活化酵素に関する研究 [The enzymatic mechanisms of resistant to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus]Jpn J Antibiot1988415523529 Japanese3216474
   PubMedGoogle Scholar
• NikiYHanakiHYagisawaMJapanese Society of Chemotherapy. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibilityJ Infect Chemother200814427929018709531
   PubMedGoogle Scholar
• NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother200915315616719554400
   PubMed Web of Science ®Google Scholar
• NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother201117451052321409533
   PubMed Web of Science ®Google Scholar
• TakesueYWatanabeAHanakiHNationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in JapanJ Infect Chemother201218681682623143280
   PubMed Web of Science ®Google Scholar
• MikuniyaTKatoYMuto-KobayashiYPrevalence of drug resistant gene and changes in susceptibility of methicillin-resistant Staphylococcus aureus strains isolated from 1990 to 2006 in Japan to antimicrobial agentsJpn J Chemother20096153740
   Google Scholar
• WatanabeTOhashiKMatsuiKKubotaTComparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicilin-resistant Staphylococcus aureusJ Antimicrob Chemother19973944714769145819
   PubMed Web of Science ®Google Scholar
• FlandroisJPFardelGCarretGEarly stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureusAntimicrob Agents Chemother19883244544572837137
   PubMed Web of Science ®Google Scholar
• AsserayNJacquelineCLe MabecqueVActivity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacyAntimicrob Agents Chemother200549285785915673789
   PubMed Web of Science ®Google Scholar
• TakahashiTMatsumotoFMiyazakiSComparison of in vitro antibacterial activity of arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureusJpn J Chemother1999472103107
   Google Scholar
• KurazonoMYamadaKHiraiYIdaTInoueMMRSA の疫学動向と各種抗菌薬の抗菌活性について. [Epidemiological survey of drug resistance of methicillin–resistant Staphylococcus aureus isolated in Japan in 2000]Jpn J Chemother2002508494499 Japanese
   Google Scholar
• MiyataAAraakeMOgawaHHanakiHHiramatsuKMRSAの Toxic shock syndrome toxin-1(TSST-1)産生に及ぼす arbekacinの作用. [Effect of Arbekacin of the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus]Jpn J Antibiotics2001547372381 Japanese11560056
   PubMedGoogle Scholar
• AraokaHBabaMTatedaKIn vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in JapanJpn J Infect Dis2012651848722274165
   PubMed Web of Science ®Google Scholar
• KataokaHIdaTIshiiYAnalysis of the influence of drug resistance factors on the efficacy of combinations of antibiotics for multidrug-resistant Pseudomonas aeruginosa isolated from hospitals located in the suburbs of Kanto area, JapanJournal of Global Antimicrobial Resistance2013129196
   Web of Science ®Google Scholar
• ZaporMJBarberMSummersAIn vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical CenterAntimicrob Agents Chemother20105473015301720404121
   PubMed Web of Science ®Google Scholar
• Overview of Habekacin Injectable Solution (additional pediatric indication)In-house document of Meiji Seika Kaisha, Ltd
   Google Scholar
• AikawaNKohnoSKakuMWatanabeAYamaguchiKTanigawaraYAn open clinical study of arbekacin 200 mg qd in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) – A clinical pharmacology studyJpn J Chemother2008563299312
   Google Scholar
• SunakawaKHoriS健康成人男性におけるアルベカシン硫酸塩400mg又は600mg投与時の安全性及び薬物動態. [Safety and pharmacokinetics of 400 and 600 mg arbekacin sulfate to healthy male volunteers]Jpn J Antibiotics201366297109 Japanese23951728
   PubMed Web of Science ®Google Scholar
• SuzukiKTanikawaKMatsuzakiTPharmacokinetics and dosing of arbekacin in preterm and term newborn infantsPediatr Int200345217517912709144
   PubMed Web of Science ®Google Scholar
• KinoshitaD新しい推奨ピーク値を目標とした新生児に対するアルベカシン1日1回投与法の検討. [Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration]Kansenshogaku Zasshi2010846727733 Japanese21226325
   PubMedGoogle Scholar
• FunatsuYHasegawaNNamkoongHPenetration of arbekacin sulfate to the lung tissueProceedings of the 52nd interscience conference on antimicrobial agents and chemotherapySeptember 9–12, 2012San Francisco Abstract No 2068
   Google Scholar
• CarcasAJGarcia-SatueJLZapaterPFrias-IniestaJTobramycin penetration into epithelial lining fluid of patients with pneumoniaClin Pharmacol Ther199965324525010096256
   PubMed Web of Science ®Google Scholar
• KimuraTSunakawaKMatsuuraNKuboHShimadaSYagoKPopulation pharmacokinetics of arbekacin, vancomycin, and panipenem in neonatesAntimicrob. Agents Chemother20044841159116715047516
   PubMed Web of Science ®Google Scholar
• KogaKKusawakeYItoYSugiokaNShibataNTakadaKEnhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfateEur J Pharm Biopharm2006641829116750354
   PubMed Web of Science ®Google Scholar
• BlaserJRiederHLLuthyRInterface-area-to-volume ratio of interstitial fluid humans determined by pharmacokinetic analysis of netilmicin in small and large skin blistersAntimicrob Agents Chemother19913558378391854165
   PubMed Web of Science ®Google Scholar
• DeeTHKozinFGentamicin and tobramycin penetration into synovial fluidAntimicrob Agents Chemother1977124548549921252
   PubMed Web of Science ®Google Scholar
• ThysJPSerruvs-SchoutensERocmansPHerchuelzAVanderlindenMPYourassowskyEAmikacin concentration in uninfected post thoracotomy pleural fluid and in serum after intravenous and intrapleural injectionChest19848545025056705579
   PubMed Web of Science ®Google Scholar
• KozakAJGerdingDNPetersonLRHallWHGentamicin intravenous infusion rate: effect on interstitial fluid concentrationAntimicrob Agents Chemother1977125606608921257
   PubMed Web of Science ®Google Scholar
• ChisholmGDWaterworthPMCalnanJSGarrodLPConcentration of antibacterial agents in interstitial tissue fluidBr Med J1973158535695734694402
   PubMed Web of Science ®Google Scholar
• LorentzenHKallehaveFKolmosHJKniggeUBulowJGottrupFGentamicin concentrations in human subcutaneous tissueAntimicrob Agents Chemoter199640817851789
   PubMed Web of Science ®Google Scholar
• RosinEEbertSUphoffTSEvansMHSchultz-DarkenNJPenetration of antibiotics into the surgical wound in a canine modelAntimicrob Agents Chemoter1989335700704
   Web of Science ®Google Scholar
• HayashiMOoiKYamadaアルベカシン硫酸塩静注後の滲出液中濃度と血中濃度を測定した4症例. [Arbekacin sulfate concentration in peripheral lymph and in serum after intravenous injection: report of four cases]Jpn J Antibiot2012653207215 Japanese23173295
   PubMedGoogle Scholar
• OkadaKKimuraTMikamoHClinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug MonitoringJ Infect Chemother20142011524486168
   PubMed Web of Science ®Google Scholar
• ShimizuAMaebashiKNiidaMS03044. Pharmacokinetic-pharmacodynamic (PK-PD) study of arbekacin using mouse MRSA thigh infection modelIn-house document of Meiji Seika Kaisha, Ltd2003
   Google Scholar
• MattieHCraigWAPechereJCDetermination of efficacy and toxicity of aminoglycosidesJ Antimicrob Chemother19892432812932681115
   PubMed Web of Science ®Google Scholar
• CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis19982611129455502
   PubMed Web of Science ®Google Scholar
• SatoRTanigawaraYKakuMAikawaNShimizuKPharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother200650113763376917065622
   PubMed Web of Science ®Google Scholar
• NegitaKYamashitaMKubotaTStudy on therapeutic drug monitoring of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus and its efficacyJpn J Pharm Health Care Sci2001272123131
   Google Scholar
• NambaraMIkeueHKawasakiETomiokaSShimokawaFTanabeKEffectiveness and adverse reactions between once daily and every other day administration of arbekacin sulfateJpn J Ther Drug Monit2003203241248
   Google Scholar
• KobayashiMSaikyoASomaKYagoKSunakawaKPharmacokinetic and pharmacodynamics (PK-PD) analysis to determine the optimal method of arbekacin administrationJpn J Chemother20065411824
   Google Scholar
• TanikazeNKomatsuMShimakawaKYamamotoIメチシリン耐性黄色ブドウ球菌肺炎に対する硫酸アルベカシン治療における PK/PD 解析の臨床的有用性. [Study of clinical significance of PK/PD (pharmacokinetics/pharmacodynamics) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection]Jpn J Chemother2004529469473 Japanese
   Google Scholar
• HwangJHLeeJHMoonMKKimJSWonKSLeeCSThe usefulness of arbekacin compared to vancomycinEur J Clin Microbiol Infect Dis20123171663166622124537
   PubMed Web of Science ®Google Scholar
• HwangJHLeeJHMoonMKKimJSWonKSLeeCSThe efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue mrsa infection: preliminary studyInfect Chemother2013451626824265951
   PubMedGoogle Scholar
• MatsumotoTHanakiHKimuraTClinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional studyJ Infect Chemother201319112813723263188
   PubMed Web of Science ®Google Scholar
• KawanoHTanigawaraYPostmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoringJpn J Ther Drug Monit20102725571
   Google Scholar
• YamamotoYIzumikawaKHashiguchiKThe efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infectionJ Infect Chemother201218224124622398881
   PubMed Web of Science ®Google Scholar
• KimuraTSunakawaKTotsukaKDose finding study on arbekacin sulfate for appropriate peak levelsJpn J Chemother2011596597604
   Google Scholar
• AraokaHBabaMTakagiSMonobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multi-drug-resistant Pseudomonas aeruginosa screened using a ‘break-point checkerboard plate’Scand J Infect Dis201042323123320001223
   PubMed Web of Science ®Google Scholar
• Mingeot-LeclercqMPTulkensPMAminoglycosides: nephrotoxicityAntimicrob Agents Chemother19994351003101210223907
   PubMed Web of Science ®Google Scholar
• SwanSKAminoglycoside nephrotoxicitySemin Nephrol199717127339000547
   PubMed Web of Science ®Google Scholar
• GiulianoRAVerpootenGAVerbistLWedeenRPDe BroeMEIn vivo uptake kinetics of aminoglycosides in the kidney cortex of ratsJ Pharmacol Exp Ther198623624704753944768
   PubMed Web of Science ®Google Scholar
• RougierFClaudeDMaurinMAminoglycoside nephrotoxicity: modeling, simulation, and controlAntimicrob Agents Chemother20034731010101612604535
   PubMed Web of Science ®Google Scholar
• ChanbersHEChemotherapy of microbial diseases antimicrobial agents: the aminoglycosidesHardmanJGLimbirdLEGoodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th editionNew YorkMcGraw-Hill200112191238
   Google Scholar
• HuyPTBMannelCMenlemansAKinetics of aminoglycoside antibiotics in perilymph in animalsLernerSAMartzGJHawkinsJEAminoglycoside OtotoxicityLittle, Brown and Company19818197
   Google Scholar
• TulkensPMClerckx-BraunFDonnezJSafety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory diseaseJ Drug Dev19881Suppl 37182
   Google Scholar
• TotsukaKShimizuKMitomiNNiizatoTAraakeMArbekacinの1日1回投与法の検討　基礎的検討及びヒトにおける体内動態. [Evaluation of once-daily administration of arbekacin]Jpn J Antibiotics1994476676692 Japanese8072176
   PubMedGoogle Scholar
• BatesDEAminoglycoside ototoxicityDrugs Today (Barc)200339427728512743643
   PubMed Web of Science ®Google Scholar
• BarclayMLKirkpatrickCMBeggEJOnce daily aminoglycoside therapy – Is it less toxic than multiple daily doses and how should it be monitored?Clin Pharmacokinet1999362899810092956
   PubMed Web of Science ®Google Scholar
• YamasobaTInner ear disorders and mitochondrial DNA mutationPractica Oto-Rhino-Laryngologica20111048533540
   Google Scholar
• HamasakiKRandoRRSpecific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafnessBiochemistry1997364012323123289315872
   PubMed Web of Science ®Google Scholar